Joxane 

Active Ingredient (s): Enoxaparin Sodium Injection.

Strength: 4000 anti-Xa IU/0.4ml

Indications

  • ● Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.
  • ● Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient.
  • ● Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.
  • ● Treatment of unstable angina and non-Q-wave myocardial infarction, in combination with acetylsalicylic acid (ASA).
  • ● Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty
  • ● Blood clot prevention in the extracorporeal circulation during haemodialysis.

Joxane 

Active Ingredient (s): Enoxaparin Sodium Injection.

Strength: 6000 anti-Xa IU/0.6ml

Indications

  • ● Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.
  • ● Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient.
  • ● Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.
  • ● Treatment of unstable angina and non-Q-wave myocardial infarction, in combination with acetylsalicylic acid (ASA).
  • ● Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty
  • ● Blood clot prevention in the extracorporeal circulation during haemodialysis.